GALMED PHARMACEUTICALS LTD. APIC, Share-based Payment Arrangement, Recognition and Exercise
GALMED PHARMACEUTICALS LTD. (GLMD) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $156.00 thousand for the 3-month period ending 2026-06-30, per its 6-K filed 2026-09-02.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2026-09-02
- GALMED PHARMACEUTICALS LTD. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2026-06-30 was $156.00K, a 56.00% increase year-over-year.
- GALMED PHARMACEUTICALS LTD. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2026-03-31 was $156.00K, a 54.46% increase year-over-year.
- GALMED PHARMACEUTICALS LTD. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-09-30 was $105.00K, a 20.45% decline year-over-year.
- GALMED PHARMACEUTICALS LTD. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-06-30 was $100.00K, a 23.08% decline year-over-year.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 12 month |
|---|---|---|---|---|
| 2026-06-30 | $156.00K 6-K · filed 2026-09-02 | $312.00K derived: sum of 2 quarters · filed 2026-09-02 | ||
| 2026-03-31 | $156.00K 6-K · filed 2026-09-02 | |||
| 2025-12-31 | $546.00K 20-F · filed 2026-03-31 | |||
| 2025-09-30 | $105.00K 6-K · filed 2025-11-26 | $205.00K derived: sum of 2 quarters · filed 2026-09-02 | $306.00K derived: sum of 3 quarters · filed 2026-09-02 | |
| 2025-06-30 | $100.00K 6-K · filed 2026-09-02 | $201.00K 6-K · filed 2025-11-26 | ||
| 2025-03-31 | $101.00K 6-K · filed 2026-09-02 | |||
| 2024-12-31 | $531.00K 20-F · filed 2026-03-31 | |||
| 2024-09-30 | $132.00K 6-K · filed 2025-11-26 | $262.00K derived: sum of 2 quarters · filed 2025-11-26 | $415.00K derived: sum of 3 quarters · filed 2025-11-26 | |
| 2024-06-30 | $130.00K 6-K · filed 2025-08-28 | $283.00K 6-K · filed 2025-11-26 | ||
| 2024-03-31 | $153.00K 6-K · filed 2025-08-28 | |||
| 2023-12-31 | $892.00K 20-F · filed 2026-03-31 | |||
| 2023-06-30 | $174.00K 6-K · filed 2024-08-28 | $471.00K derived: sum of 2 quarters · filed 2024-08-28 | ||
| 2023-03-31 | $297.00K 6-K · filed 2024-08-28 | |||
| 2022-12-31 | $1.30M 20-F · filed 2025-04-02 | |||
| 2022-06-30 | $446.00K 6-K · filed 2023-08-09 | $903.00K derived: sum of 2 quarters · filed 2023-08-09 | ||
| 2022-03-31 | $457.00K 6-K · filed 2023-08-09 | |||
| 2021-12-31 | $1.89M 20-F · filed 2024-04-04 | |||
| 2021-06-30 | $472.00K 6-K · filed 2022-08-04 | $943.00K derived: sum of 2 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $471.00K 6-K · filed 2022-08-04 | |||
| 2020-12-31 | $2.07M 20-F · filed 2023-03-29 | |||
| 2020-06-30 | $581.00K 6-K · filed 2021-08-05 | $1.10M derived: sum of 2 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $515.00K 6-K · filed 2021-08-05 | |||
| 2019-12-31 | $2.23M 20-F · filed 2021-03-18 | |||
| 2019-06-30 | $591.00K 6-K · filed 2020-08-06 | $1.01M derived: sum of 2 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $416.00K 6-K · filed 2020-08-06 | |||
| 2018-12-31 | $1.78M 20-F · filed 2020-03-12 | |||
| 2018-06-30 | $87.00K 6-K · filed 2019-08-05 | $417.00K 6-K · filed 2018-08-02 | ||
| 2018-03-31 | $330.00K 6-K · filed 2019-08-05 | |||
| 2017-12-31 | $1.39M 20-F · filed 2019-03-13 | |||
| 2017-06-30 | $709.00K 6-K · filed 2017-07-31 | |||
| 2016-12-31 | $1.63M 20-F · filed 2018-03-13 | |||
| 2016-06-30 | $1.06M 6-K · filed 2017-06-23 | |||
| 2015-12-31 | $970.00K 20-F · filed 2017-03-23 | |||
| 2014-12-31 | $601.00K 20-F · filed 2016-03-22 | |||
| 2013-12-31 | $10.85M 20-F · filed 2015-03-31 | |||
| 2012-12-31 | $208.00K 20-F · filed 2015-03-31 |